Daunorubicin reduces MBNL1 titration by expanded CUG repeat RNA and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy

Author:

Chakraborty M.123,Sellier Chantal4,Ney Michel4,Villa Pascal5,Charlet-Berguerand Nicolas4,Artero R.123ORCID,Llamusi B.123

Affiliation:

1. Translational Genomics Group, Incliva Health Research Institute, Valencia, Spain

2. Department of Genetics and Interdisciplinary Research Structure for Biotechnology and Biomedicine (ERI BIOTECMED), University of Valencia, Valencia, Spain

3. CIPF-INCLIVA joint unit, Valencia, Spain

4. Translational Medicine and Neurogenetics, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM U964, CNRS UMR7104, University of Strasbourg, 1 Rue Laurent Fries, 67400 Illkirch-Graffenstaden, France

5. PCBIS Plate-forme de Chimie Biologique Intégrative de Strasbourg CNRS UMS 3286, Labex Medalis, ESBS, 300 Boulevard Sébastien Brant, 67412 Illkirch, France

Abstract

Myotonic dystrophy (DM) is a dominantly inherited neuromuscular disorder caused by expression of mutant DMPK transcripts containing expanded CUG repeats. Pathogenic RNA sequesters the muscleblind-like (MBNL) proteins, causing alterations of RNA metabolism. Cardiac dysfunction represents the second most common cause of death in DM1 patients. However, the contribution of MBNL titration in DM1 cardiac dysfunction is unclear. We overexpressed Muscleblind (Mbl), Drosophila MBNL orthologue, in cardiomyocytes of DM1 model flies and observed a rescue of heart dysfunctions, which are characteristic of these model flies and resemble cardiac defects observed in patients. We also identified a drug, Daunorubicin hydrochloride, that directly binds to CUG repeats and alleviates Mbl titration in Drosophila DM1 cardiomyocytes, resulting into missplicing rescue and cardiac function recovery. These results demonstrate the relevance of Mbl titration by expanded CUG RNA in cardiac dysfunctions in DM1, and highlight the potential of strategies aimed at inhibit this protein-RNA interaction to recover normal cardiac function.

Funder

Instituto de Salud Carlos III

ERARE

European Research Council

AFM-Téléthon

GIS-Institut des Maladies Rares

Generalitat Valenciana

Publisher

The Company of Biologists

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology and Microbiology (miscellaneous),Medicine (miscellaneous),Neuroscience (miscellaneous)

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2;International Journal of Molecular Sciences;2022-09-10

2. Disrupting the Molecular Pathway in Myotonic Dystrophy;International Journal of Molecular Sciences;2021-12-08

3. Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1;Frontiers in Aging Neuroscience;2021-11-15

4. Drosophila Heart as a Model for Cardiac Development and Diseases;Cells;2021-11-08

5. Cardiac Pathology in Myotonic Dystrophy Type 1;International Journal of Molecular Sciences;2021-11-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3